Filing Details

Accession Number:
0001209191-16-136838
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-12 17:14:35
Reporting Period:
2016-08-10
Filing Date:
2016-08-12
Accepted Time:
2016-08-12 17:14:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818033 Heron Therapeutics Inc. HRTX Pharmaceutical Preparations (2834) 942875566
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1555089 Robert Rosen 123 Saginaw Drive
Redwood City CA 94063
President & Cco Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-10 100,000 $7.20 102,640 No 4 M Direct
Common Stock Disposition 2016-08-10 87,600 $23.21 15,040 No 4 S Direct
Common Stock Disposition 2016-08-10 12,400 $23.89 2,640 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-08-10 100,000 $0.00 100,000 $7.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
825,000 2023-05-01 No 4 M Direct
Footnotes
  1. The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in 2015.
  2. The range of sales prices received was $22.78 to $23.77. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  3. The range of sales prices received was $23.78 to $24.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  4. At the date of filing, 444,532 shares of the options granted pursuant to the underlying awards were fully vested and exercisable.